Securities Registration Statement (simplified Form) (s-3/a)

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 8, 2022

REGISTRATION NO. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

AMENDMENT NO. 1
TO

FORM S-3

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

BIOTRICITY INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of

incorporation or organization)

30-0983531 I.R.S. Employer Identification Number

203 Redwood Shores Parkway, Suite 600

Redwood City, CA 94065

(650) 832-1626

(Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

Waqaas Al-Siddiq, CEO

Biotricity Inc.

203 Redwood Shores Parkway, Suite 600

Redwood City, CA 94065

(650) 832-1626

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Gregory Sichenzia, Esq.

Sichenzia Ross Ference LLP

1185 Avenue of the Americas, 31^ST Floor

New York, New York 10036

Phone: 212-930-9700

Fax: 212-930-9725

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plants, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

The information in this preliminary prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities, nor does it seek an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted.

Subject to Completion, Dated April 8, 2022

PROSPECTUS

10,947,201 Shares of Common Stock

BIOTRICITY INC.

This prospectus relates to the public offering of up to 10,947,201 shares of our common stock, par value $0.001 per share (the “Common Stock”), by the selling stockholder which is comprised of shares of Common Stock issued to the selling stockholders upon the conversion of convertible promissory notes issued to certain selling stockholders pursuant to private placements between June 2020 and February 2021, shares of Common Stock and shares of Common Stock underlying Exchangeable Shares issued to certain investors in connection with the Company’s reverse take-over of iMedical Innovations Inc., shares of Common Stock issued to advisors and consultants of the Company between February 2016 and January 2022 as share-based compensation for services, and shares of Common Stock issued to certain shareholders in connection with private placements between February 2016 and June 2020. Please see “Description of Transactions” beginning on page 4 of this prospectus.

We will not receive any proceeds from the sale of shares of common stock by the selling stockholders.

The selling stockholders may sell or otherwise dispose of the shares of Common Stock covered by this prospectus in a number of different ways and at varying prices. The prices at which the selling stockholders may sell the shares will be determined by prevailing market prices for the shares or in negotiated transactions. We provide more information about how the selling stockholders may sell or otherwise dispose of their shares of Common Stock in the section titled “Plan of Distribution.” The selling stockholders will pay all brokerage fees and commissions and similar expenses. We will pay all expenses (except brokerage fees and commissions and similar expenses) relating to the registration of the shares of Common Stock with the Securities and Exchange Commission.

We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision.

Our Common Stock is currently traded on the Nasdaq Capital Market under the symbol “BTCY” On April 7, 2022, the last reported sales price for our Common Stock was $2.11 per share.

The securities offered by this prospectus involve a high degree of risk. See “Risk Factors” beginning on page 4, in addition to Risk Factors contained in the applicable prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

This prospectus is dated ______, 2022

Table of Contents

	Page
About this Prospectus	1
Cautionary Statements Regarding Forward-Looking Statements	1
Prospectus Summary	2
The Offering	3
Risk Factors	4
Use of Proceeds	4
Description of Transactions with the Selling Stockholders	4
The Selling Stockholders	6
Description of Capital Stock	13
Plan of Distribution	11
Legal Matter	16
Experts	16
Where You Can find More Information	17
Incorporation of Certain Documents by Reference	17

You may only rely on the information contained in this prospectus or that we have referred you to. We have not authorized anyone to provide you with different information. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities other than the Common Stock offered by this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any Common Stock in any circumstances in which such offer or solicitation is unlawful. Neither the delivery of this prospectus nor any sale made in connection with this prospectus shall, under any circumstances, create any implication that there has been no change in our affairs since the date of this prospectus or that the information contained by reference to this prospectus is correct as of any time after its date.

ABOUT THIS PROSPECTUS

This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to tactual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled “Where You Can Find Additional Information.”

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This prospectus and the documents and information incorporated by reference in this prospectus include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include statements concerning:

	●	our possible or assumed future results of operations;

	●	our business strategies;

	●	our ability to attract and retain customers;

	●	our ability to sell additional products and services to customers;

	●	our cash needs and financing plans;

	●	our competitive position;

	●	our industry environment;

	●	our potential growth opportunities;

	●	expected technological advances by us or by third parties and our ability to leverage them;

	●	the effects of future regulation; and

	●	the effects of competition.

All statements in this prospectus and the documents and information incorporated by reference in this prospectus that are not historical facts are forward-looking statements. We may, in some cases, use terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions or the negative of such items that convey uncertainty of future events or outcomes to identify forward-looking statements.

Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made and we undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

PROSPECTUS SUMMARY

This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing in our Company. You should carefully read the entire prospectus, including all documents incorporated by reference herein. In particular, attention should be directed to our “Risk Factors,” “Information With Respect to the Company,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the financial statements and related notes thereto contained herein or otherwise incorporated by reference hereto, before making an investment decision.

All brand names or trademarks appearing in this report are the property of their respective holders. Unless the context requires otherwise, references in this report to “Biotricity,” the “Company,” “we,” “us” and “our” refer to Biotricity Inc., a Nevada corporation.

Corporate Information

Our Company was incorporated on August 29, 2012 in the State of Nevada. Our principal executive office is located at 203 Redwood Shores Parkway, Suite 600, Redwood City, California, and our telephone number is (650) 832-1626. Our website address is www.biotricity.com. The information on our website is not part of this prospectus. Our fiscal year end is March 31.

Business Overview

Biotricity Inc. is a medical technology company focused on biometric data monitoring solutions. Our aim is to deliver innovative, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. We approach the diagnostic side of remote patient monitoring by applying innovation within existing business models where reimbursement is established. We believe this approach reduces the risk associated with traditional medical device development and accelerates the path to revenue. In post-diagnostic markets, we intend to apply medical grade biometrics to enable consumers to self-manage, thereby driving patient compliance and reducing healthcare costs. We intend to first focus on a segment of the diagnostic mobile cardiac telemetry market, otherwise known as MCT, while providing our chosen markets with the capability to also perform other cardiac studies.

We developed our FDA-cleared Bioflux® MCT technology, comprised of a monitoring device and software components, which we made available to the market under limited release on April 6, 2018, in order to assess, establish and develop sales processes and market dynamics. The fiscal year ended March 30, 2020 marked the Company’s first year of expanded commercialization efforts, focused on sales growth and expansion. We have expanded our sales efforts to 26 states, with intention to expand further and compete in the broader US market using an insourcing business model. Our technology has a large potential total addressable market, which can include hospitals, clinics and physicians’ offices, as well as other IDTFs. We believe our solution’s insourcing model, which empowers physicians with state-of-the-art technology and charges technology service fees for its use, has the benefit of a reduced operating overhead for the Company, and enables a more efficient market penetration and distribution strategy. This, when combined with the value the Company’s solution in the diagnosis of cardiac arrhythmias, enhancement of patient outcomes, improved patient compliance, and the corresponding reduction of healthcare costs, is driving growth and increasing revenues.

We are a technology company focused on earning utilization-based recurring technology fee revenue. The Company’s ability to grow this type of revenue is predicated on the size and quality of its sales force and their ability to penetrate the market and place devices with clinically focused, repeat users of its cardiac study technology. The Company plans to grow its sales force in order to address new markets and achieve sales penetration in the markets currently served. The Company has also developed or is developing several other ancillary technologies, which will require application for further FDA clearances, which the Company anticipates applying for within the next to twelve months. Among these are:

	●	advanced ECG analysis software that can analyze and synthesize patient ECG monitoring data with the purpose of distilling it down to the important information that requires clinical intervention, while reducing the amount of human intervention necessary in the process;

	●	the Bioflux® 2.0, which is the next generation of our award winning Bioflux®

During fiscal 2021, the Company announced that it received a 510(k) clearance from the FDA for its Bioflux Software II System, engineered to improve workflows and reduce estimated analysis time from 5 minutes to 30 seconds. ECG monitoring requires significant human oversight to review and interpret incoming patient data to discern actionable events for clinical intervention, highlighting the necessity of driving operational efficiency. This improvement in analysis time reduces operational costs and allows the company to continue to focus on excellent customer service and industry-leading response times to physicians and their at-risk patients. Additionally, these advances mean we can focus our resources on high-level operations and sales to help drive greater revenue.

During the latter part of fiscal 2022, the Company completed development of its Biocare system, which is designed to service the chronic care monitoring needs of clinics and cardiac patients on an ongoing basis. The Company concurrently launched its Bioheart product, which is a wearable consumer device that is a personal heart monitor which allows the consumer to access constant and accurate heart rhythm monitoring.

In January 2022 the Company announced that it has received the 510(k) FDA clearance of its Biotres patch solution, which is a novel product in the field of Holter monitoring. This three-lead technology can provide connected Holter monitoring that is designed to produce more accurate arrythmia detection than is typical of competing remote patient monitoring solutions. The Company has already developed further improvements to this technology that are expected to follow, which are not known by the Company to be currently available in the market for clinical and consumer patch solution applications.

THE OFFERING

Issuer		Biotricity Inc.

Common Stock Offered by the Selling Stockholder		10,947,201 shares

Common Stock Outstanding before this offering		49,927,049 shares

Common Stock Outstanding after this offering		49,927,049 shares

Terms of this Offering		The selling stockholders will determine when and how it will sell the Common Stock offered in this Prospectus, as described in “Plan of Distribution.”

Use of Proceeds		The selling stockholders will receive the proceeds from the sale of shares of Common Stock offered hereby. We will not receive any proceeds from the sale of the shares of Common Stock offered hereby. We will pay the expenses (other than any broker’s commissions and similar expenses) of this offering.

Trading Market		Our Common Stock is listed on the Nasdaq Capital Market under the symbol “BTCY”

RISK FACTORS

Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other factors described in our most recent Annual Report on Form 10-K, as supplemented and updated by subsequent quarterly reports on Form 10-Q and current reports on Form 8-K that we have filed or will file with the SEC, which are incorporated by reference into this prospectus.

Our business, affairs, prospects, assets, financial condition, results of operations and cash flows could be materially and adversely affected by these risks. For more information about our SEC filings, please see “Where You Can Find More Information”.

USE OF PROCEEDS

This prospectus relates to shares of our Common Stock that may be offered and sold from time to time by the selling stockholders. We will not receive any of the proceeds resulting from the sale of Common Stock by the selling stockholders.

DESCRIPTION OF TRANSACTIONS WITH THE SELLING STOCKHOLDERS

In connection with the Company’s reverse take-over of iMedical Innovations, Inc. in February 2016, certain investors were issued Exchangeable Shares, which were convertible into shares of the Company’s Common Stock. Certain of those Exchangeable Shares that have not yet been converted and which are convertible on a one for one basis into 1,442,782 shares of the Company’s Common Stock are being registered pursuant to this prospectus.

Between February 2016 and April 2022, we issued shares of Common Stock to certain Selling Shareholders who were advisors and consultants to the Company. Of those shares 1,832,910 shares are being registered pursuant to this prospectus.

Between February 2016 and June 2020, we issued shares of Common Stock to certain Selling Stockholders pursuant to private placement transactions. Of those shares, 1,809,432 shares are being registered pursuant to this prospectus.

During the year ended March 31, 2021, the Company issued $11,275,500 (face value) in two series of convertible promissory notes (the “Series A Notes”) sold under subscription agreements to accredited investors, of which approximately $700,000 remains to be converted into shares of the Company’s common stock. The Series A Notes mature one year from the final closing date of the offering and accrue interest at 12% per annum.

For the first series of Series A Notes, commencing six months following the issuance date of such Series A Notes, and at any time thereafter (provided the holder of such Series A Notes has not received notice of the Company’s intent to prepay the note), at the sole election of such holder, any amount of the outstanding principal and accrued interest of this note (the “Series A Outstanding Balance”) may be converted into that number of shares of Common Stock equal to: (i) the Series A Outstanding Balance divided by (ii) 75% of the volume weighted average price of the Common Stock for the five (5) trading days prior to the Conversion Date (the conversion price).

For the first series of Series A Notes, the notes will automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the twenty (20) consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price will be equal to 75% of the volume weighted average price of the common stock for the twenty (20) trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest.

For the second series of Series A Notes, the notes will be convertible into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to the lower of $4.00 per share or 75% of the volume weighted average price of the common stock for the five (5) trading days prior to the conversion date.

For the second series of Series A Notes, the notes will automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the twenty (20) consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price will be equal to the lower of $4.00 per share or 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to the lower of $4.00 per share or 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest.

The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a three-year term from date of issuance and an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing.

The Company is obligated to pay the placement agent of the first series of Series A Notes a 12% cash fee for $8,925,550 (face value) of the notes and 2.5% cash fee and other sundry expenses for the remaining $2,350,000 (face value) of the notes.

Net proceeds to the Company from Series A Notes issuance up to March 31, 2021 amounted to $10,135,690 after payment of the relevant financing related fees.

The Company is also obligated to issue warrants to the placement agent that have a 10-year term and cover 12% of funds raised for $8,925,550 (face value) of the notes (first series) of which approximately $200,000 remains to be converted into shares of the Company’s common stock and 2.5% of funds raised for the remaining $2,350,000 (face value) of notes (second series) of which approximately $500,000 remains to be converted into shares of the Company’s common stock, with an exercise price that is 120% of the 20-day volume weighted average price of the Company’s common shares at the time final closing.

Prior to final closing, the warrants’ exercise price is variable and will not be struck until that date.

Prior to January 8, 2021 (final closing date), the Company determined that the conversion and redemption features, investor warrants and placement agent warrants contained in those Series A Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liabilities associated with the embedded conversion and redemption features, as well as investor warrants and placement agent warrants. The initial fair value of the derivative liabilities generated as a result of issuing the Series A Notes that were issued until March 31, 2021 was $6,932,194.

Subsequently, the exercise price of all warrants was concluded and locked as of January 8, 2021. Since the exercise price was no longer a variable, the Company concluded that the noteholder and placement agent warrants should no longer be accounted for as a derivative liability in accordance with ASC 815 guidelines related to equity indexation and classification. The derivative liabilities related to those warrants were therefore marked to market as of January 8, 2021 and then transferred to equity (collectively, “End of warrants derivative treatment”).

At March 31, 2021, 733,085 common shares were issued and 18,402 common shares would be issued subsequent to year-end.

In addition, during the year ended March 31, 2021, the Company also issued $1,312,500 (face value) of convertible promissory notes (“Series B Notes”) to various accredited investors, of which $840,000 have not yet been converted.

Commencing six months following the issuance date of such Series B Notes, and at any time thereafter, subject to the Company’s Conversion Buyout clause (as defined in the Series B Notes), at the sole election of the holder, any amount of the outstanding principal and accrued interest of the note (the “Series B Outstanding Balance”) may be converted into that number of shares of Common Stock equal to: (i) the Series B Outstanding Balance divided by (ii) the Conversion Price. Partial conversions of the note shall have the effect of lowering the outstanding principal amount of the note. The holder may exercise such conversion right by providing written notice to the Company of such exercise in a form reasonably acceptable to the Company (a “conversion notice”). Conversion price means (subject in all cases to proportionate adjustment for stock splits, stock dividends, and similar transactions), seventy-five percent (75%) multiplied by the average of the three (3) lowest closing prices during the previous ten (10) trading days prior to the receipt of the conversion notice.

The Series B Notes will automatically convert into common stock upon a merger, consolidation, exchange of shares, recapitalization, reorganization, as a result of which the Company’s common stock shall be changed into another class or classes of stock of the Company or another entity, or in the case of the sale of all or substantially all of the assets of the Company other than a complete liquidation of the Company. Within the first 180 days after the issuance date, the Company may, at its discretion redeem the notes for 115% of their face value plus accrued interest.

The Company is obligated to issue warrants that accompany the convertible notes and provide 50% warrant coverage. The warrants have a three-year term from date of issuance and an exercise price that is $1.06 per share for 100,000 warrant shares and $1.50 per share for 212,500 warrant shares.

Net proceeds to the Company from convertible note issuances to March 31, 2021 amounted to $1,240,000 after the original issuance discount as well as payment of the financing related fees. The Company determined that the conversion and redemption features contained in the Series B Notes represented a single compound derivative liability that meets the requirements for liability classification under ASC 815. The Company accounted for these obligations by determining the fair value of the related derivative liability associated with the embedded conversion and redemption features. The initial fair value of the derivative liabilities generated as a result of issuing the Series B Notes was $497,042.

In connection with the foregoing, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering.

SELLING STOCKHOLDERS

Name of Selling Stockholder		Number of Shares Beneficially Owned #		Shares of Common Stock Offered by the Selling Stockholder		Shares Underlying Warrants		Shares Underlying Exchangeable Shares		Unconverted Convertible Notes Outstanding (assumed VWAP of $3)	Unregistered Shares Beneficially Owned After Offering Number			% of Shares Owned After Offering Percent

1903790 ONTARIO INC	⁽⁷⁾		544,711		60,000		-					484,711			*
2427304 Ontario Inc.	⁽⁵⁾		111,793		60,000		-		111,793			51,793			*
Abdulla Silim (1)	⁽⁵⁾		11,969		11,969		-		11,969			-			-
ABRAR HUSSAIN	⁽⁷⁾		60,000		60,000		-					-			-
Albert Landstrom	⁽³⁾		60,425		-		60,425					60,425			*
Ali Bokhari (1)	⁽⁵⁾		11,969		11,969		-		11,969			-			-
ALISON SLORACH	⁽⁷⁾		13,333		13,333		-					-			-
ALLEN GABRIEL	⁽¹⁾		93,999		46,829		47,170					47,170			*
ALLIANCE TRUST COMPANY	⁽¹⁾		182,302		87,962		94,340					94,340			*
ALOK AGRAWAL	⁽¹⁾		10,303		4,407		5,896					5,896			*
AMER A SAMAD	⁽⁷⁾		35,883		35,883		-					-			-
ANSARI AMERICAN HOLDINGS LLC	⁽⁷⁾		1,436,322		60,000		-					1,376,322			2.76	%
ARTHUR HIESS	^{(7) (8)}		182,948		60,000		-					122,948			*
Arthur Steinberg	⁽¹⁾		22,853		22,853		-					-			-
ASHOK PATEL	⁽¹⁾		22,529		10,737		11,792					11,792			*
ASIAN GATEWAY LTD	⁽¹⁾		112,336		53,374		58,962					58,962			*
ASIF MUSTAFA	⁽⁷⁾		59,846		60,000		-					(154	)		-
Atik Nakrawala (1)	⁽⁵⁾		2,393		2,393		-		2,393			-			-
BARRET MARSHALL MILLER	⁽¹⁾		9,006		4,289		4,717					4,717			*
BARRY PRESSMAN	⁽⁷⁾		148,490		60,000		-					88,490			*
BARRY SAXE	⁽¹⁾		22,556		10,764		11,792					11,792			*
BASIL CHRISTAKOS	⁽⁷⁾		661		661		-					-			-
BLAINE 2000 REVOCABLE TRUST	⁽¹⁾		208,963		114,623		94,340					94,340			*
BMM CAPITAL LLC	⁽¹⁾		90,058		42,888		47,170					47,170			*
BRADLEY & LORI ABESON REV FAMILY TRUST	⁽¹⁾		31,546		22,584		8,962					8,962			*
BRIAN LANGHAM	⁽¹⁾		68,483		33,106		35,377					35,377			*
BRIAN LONNER	⁽¹⁾		112,765		53,803		58,962					58,962			*
BRIAN SKILLERN	⁽¹⁾		45,000		21,415		23,585					23,585			*
BRIAN WHEELER	⁽¹⁾		25,424		25,424		-					-			-
BRUCE CLARKE & PAULA IGNATOWICZ TTEES	⁽⁷⁾		13,500		13,500		-					-			-
BRUCE MCFADDEN	⁽⁷⁾		3,900		3,900		-					-			-
BURT STANGARONE	⁽¹⁾		62,943		29,924		33,019					33,019			*
CALCOTT FAMILY TRUST	⁽¹⁾		116,267		69,097		47,170					47,170			*
CHARLES G GATES	⁽¹⁾		32,211		32,211		-					-			-
CHITAYAT HOLDINGS LLC	⁽¹⁾		45,158		21,573		23,585					23,585			*
CHRIS DEGROAT	⁽⁷⁾		1,032		1,032		-					-			-
CHRISTOPHER CLARK	⁽³⁾		83,349		83,349		-					-			-

Name of Selling Stockholder		Number of Shares Beneficially Owned #		Shares of Common Stock Offered by the Selling Stockholder		Shares Underlying Warrants		Shares Underlying Exchangeable Shares	Unconverted Convertible Notes Outstanding (assuming VWAP of $3)		Unregistered Shares Beneficially Owned After Offering Number		% of Shares Owned After Offering Percent

CHRISTOPHER HUBBARD	⁽⁷⁾		14,286		14,286		-					-		-
CHRISTOPHER P GUTEK	⁽¹⁾		33,865		10,280		23,585					23,585		*
CLAYTON M SNOOK	⁽¹⁾		21,403		9,611		11,792					11,792		*
CLAYTON STRUVE	⁽¹⁾		156,908		95,587		61,321					61,321		*
COHEN FAMILY TRUST	⁽¹⁾		91,539		42,482		49,057					49,057		*
COLLEGIATE TUTORING INC	⁽¹⁾		16,485		7,051		9,434					9,434		*
CONNIFF FAMILY TRUST	⁽¹⁾		21,477		9,685		11,792					11,792		*
COREY DEUTSCH	⁽⁷⁾		50,000		50,000		-					-		-
CRAIG BORDON	⁽¹⁾		51,909		23,607		28,302					28,302		*
CRISTIAN JOSE LAPRIDA	⁽⁷⁾		16,666		16,666		-					-		-
Dan Mancuso	⁽³⁾		6,868		-		6,868					6,868		*
DAN’S DOORS & GLASS LIMITED	⁽⁷⁾		24,843		24,843		-					-		-
David Allen	⁽³⁾		5,000		-		5,000					5,000		*
DAVID JONG	⁽⁷⁾		16,850		16,850		-					-		-
DAVID LIEPERT	⁽⁶⁾		25,000		25,000		-					-		-
DAVID RICHARD JOHNSON TTEE	⁽⁷⁾		11,532		11,532		-					-		-
DAVID SLORACH	⁽⁷⁾		27,619		27,619		-					-		-
DAVID ZEHARIA	⁽⁷⁾		140,608		60,000		-					80,608		*
DELL DARRELL ROLAND	⁽¹⁾		12,798		12,798							-		-
DEREK SLORACH	⁽⁷⁾		6,667		6,667		-					-		-
DIANE DOWSETT	⁽⁷⁾		20,993		20,993		-					-		-
DONALD P SESTERHENN	⁽⁷⁾		14,300		14,300		-					-		-
DONALD R CROWLEY	⁽¹⁾		40,248		40,248		-					-		-
DOUGLAS KNIGHTON	⁽¹⁾		46,590		22,533		24,057					24,057		*
DRAPER INC	⁽⁷⁾		5,000		5,000		-					-		-
DUE MONDI INVESTMENTS LTD	⁽¹⁾		22,556		10,764		11,792					11,792		*
DUNLAP CAPITAL PARTNERS	⁽²⁾		580,148		273,544		306,604			201,818		306,604		*
DYKE ROGERS	⁽⁷⁾		18,857		18,857		-					-		-
EDWARD ROTTER	⁽¹⁾		90,008		42,838		47,170					47,170		*
EDWIN ROBERSON	⁽⁷⁾		36,193		36,193		-					-		-
EKM CAPITAL LLC	⁽¹⁾		9,006		4,289		4,717					4,717		*
ELDORET LLC	⁽¹⁾		92,120		44,950		47,170					47,170		*
ELEVEN 11 FINANCIAL LLC	⁽¹⁾		41,218		41,218		-					-		-
ELISE HENDRICKSEN	⁽⁷⁾		38,287		38,287		-					-		-
ERNEST W MOODY TTEE	⁽⁷⁾		169,739		60,000		-					109,739		*
FAISAL B JOSEPH	⁽⁶⁾		97,500		60,000		-					37,500		*
FRANCIS LYMBURNER	⁽¹⁾		305,284		147,737		157,547					157,547		*
FRED BIALEK	⁽¹⁾		44,977		21,392		23,585					23,585		*
G&D CONNIFF LLC	⁽¹⁾		21,477		9,685		11,792					11,792		*
Gary Saccaro	⁽³⁾		138,444		-		138,444					138,444		*
GARY W LEVINE	⁽¹⁾		90,288		43,118		47,170					47,170		*
GEORGE MARTIN	⁽¹⁾		103,197		46,593		56,604					56,604		*
GERALD A TOMSIC 1995 TRUST	⁽¹⁾		45,839		22,254		23,585					23,585		*
GERALD MCBRIDE	⁽¹⁾		181,930		87,590		94,340					94,340		*
GREG SYMONS	⁽⁷⁾		43,333		43,333		-					-		-
Gregory Gomes	⁽¹⁾		43,767		20,182		23,585			20,182		23,585		*
GUILLERMO IVANISSEVICH	⁽⁶⁾		10,000		10,000		-					-		-
Harry Striplin	⁽³⁾		5,295		-		5,295					5,295		*
HASAN AHMED MALIK	⁽⁷⁾		28,571		28,571		-					-		-
HAZEM ALGENDI	⁽³⁾		185		185		-					-		-

Name of Selling Stockholder		Number of Shares Beneficially Owned #		Shares of Common Stock Offered by the Selling Stockholder		Shares Underlying Warrants		Shares Underlying Exchangeable Shares		Unconverted Convertible Notes Outstanding (assuming VWAP of $3)		Unregistered Shares Beneficially Owned After Offering Number		% of Shares Owned After Offering Percent

HELIOS ALPHA FUNDS LP	⁽²⁾		1,388,824		704,862		683,962						683,962		1.37	%
HUNSE INVESTMENTS LP	⁽¹⁾		27,118		12,967		14,151						14,151		*
Idris Elbakri (1)	⁽⁵⁾		71,816		60,000		-		71,816				11,816		*
IMRAN TOUFEEQ	⁽⁷⁾		18,392		18,392		-						-		-
IRTH COMMUNICATIONS LLC	⁽⁶⁾		60,000		60,000		-						-		-
ISA AL-KHALIFA	⁽⁷⁾		2,814,594		60,000		-						2,754,594		5.52	%
JACOB ROSENBERG	⁽¹⁾		70,642		47,057		23,585						23,585		*
JAMES E BUTCHER	⁽¹⁾		22,420		22,420		-						-		-
JAMES G DIEMERT	⁽¹⁾		45,437		21,852		23,585						23,585		*
JASON CHIRIANO	⁽¹⁾		103,009		55,839		47,170						47,170		*
JAVIER SANCHEZ	⁽⁷⁾		11,279		11,279		-						-		-
JEFFREY TARRAND	⁽¹⁾		45,112		21,527		23,585						23,585		*
JEFFREY WOO	⁽⁶⁾		299,229		60,000		-						239,229		*
JENNIFER COOK	⁽⁵⁾		612,107		60,000		-		478,774				552,107		1.11	%
JESSICA ASLANIDIS	⁽⁶⁾		128,048		60,000		-						68,048		*
JIMMY GU	⁽⁶⁾		120,714		60,000		-						60,714		*
JOE MARTIN	⁽¹⁾		34,592		16,903		17,689						17,689		*
JOHN DUSHINSKI	⁽⁵⁾		370,742		60,000		-		179,540				310,742		*
JOHN NOLE	⁽³⁾		3,774		3,774		-						-		-
JOHN SILVESTRI	⁽⁷⁾		38,287		38,287		-						-		-
JOHN ZIEGLER	⁽⁷⁾		83,333		60,000		-						23,333		*
JOSEPH HOSTETLER	⁽⁷⁾		12,712		12,712		-						-		-
JOSEPH MANZI	⁽⁷⁾		15,000		15,000		-						-		-
JUHA TUOMINEN	⁽¹⁾		145,523		86,561		58,962						58,962		*
JULIE M OSBORNE	⁽⁷⁾		6,667		6,667		-						-		-
KAM CAPITAL LLC	⁽¹⁾		9,006		4,289		4,717						4,717		*
KAMALJIT KHARA	⁽¹⁾		50,804		50,804		-						-		-
KEITH GELLES	⁽¹⁾		229,793		135,453		94,340						94,340		*
KENNETH LISZEWSKI	⁽¹⁾		14,326		7,251		7,075						7,075		*
KENT H ELLIOTT	⁽¹⁾		83,326		59,741		23,585						23,585		*
KEVIN EIKE	⁽¹⁾		66,602		47,734		18,868						18,868		*
KIM MCKENZIE	⁽⁷⁾		24,692		24,692		-						-		-
LEANNE DOLAN	⁽⁷⁾		3,898		3,898		-						-		-
LEONARD MAZUR	⁽⁷⁾		132,794		60,000		-						72,794		*
LIFESTYLE HEALTHCARE LLC	⁽⁶⁾		421,823		60,000		-						361,823		*
LORRAINE MAXFIELD	⁽³⁾		2,014		2,014		-						-		-
LOVESTRONG SHAH INC	⁽⁶⁾		6,250		6,250		-						-		-
MALAKA EL-AILY	⁽⁷⁾		15,866		15,866		-						-		-
MARC COHEN	⁽¹⁾		49,721		23,778		25,943						25,943		*
MARK AZZOPARDI	⁽¹⁾		11,792		11,792		-						-		-
MARK SANCHEZ	⁽⁶⁾		9,143		9,143		-						-		-
MARK SPATES	⁽¹⁾		90,078		42,908		47,170						47,170		*
MARK SUWYN	⁽¹⁾		314,496		149,402		165,094				60,546		165,094		*
MARTA WYPYCH	⁽³⁾		40,737		40,737		-						-		-
MARTIN BUTTERICK	⁽⁷⁾		25,524		25,524		-						-		-
Martin Vidou	⁽⁶⁾		4,167		4,167		-						-		-
Mason Sexton	⁽³⁾		5,284		-		5,284						5,284		*
MERRI MOKEN	⁽¹⁾		45,892		22,307		23,585						23,585		*

Name of Selling Stockholder		Number of Shares Beneficially Owned #		Shares of Common Stock Offered by the Selling Stockholder		Shares Underlying Warrants		Shares Underlying Exchangeable Shares		Unconverted Convertible Notes Outstanding (assuming VWAP of $3)		Unregistered Shares Beneficially Owned After Offering Number		% of Shares Owned After Offering Percent

MICHAEL AHEARN	⁽¹⁾		40,524		19,298		21,226						21,226		*
MICHAEL G CHIECO	⁽¹⁾		36,787		17,919		18,868						18,868		*
MICHAEL GINDER	⁽¹⁾		44,940		21,355		23,585						23,585		*
MIDAS RIVER INC	⁽⁶⁾		40,318		40,318		-						-		-
MIKE ZIMMERMAN	⁽¹⁾		40,563		19,337		21,226						21,226		*
MIR AMIR ALI	^{(6) (9)}		1,146,345		1,146,345		-						-		-
MIS EQUITY STRATEGIES LP	⁽¹⁾		45,354		21,769		23,585						23,585		*
MOHAMMAD JAINAL BHUIYAN	⁽³⁾		587,045		490,000		97,045						97,045		*
MOHAMMAD SIDDIQUI	⁽⁷⁾		646,345		60,000		-						586,345		1.17	%
MONTE ANGLIN	⁽¹⁾		22,579		10,787		11,792						11,792		*
MUNRO FASTENINGS & TEXTILES	⁽⁶⁾		14,286		14,286		-						-		-
Naveed Malik (1)	⁽⁵⁾		502,713		60,000		-		502,713				442,713		*
NICHOLAS ADAMS	⁽¹⁾		44,940		21,355		23,585						23,585		*
NICK PANAYOTOU	⁽¹⁾		587,260		304,241		283,019						283,019		*
NICKOLAY KUKEKOV	⁽³⁾		307,045		210,000		97,045						97,045		*
NOAH ANDERSON	⁽¹⁾		83,261		36,091		47,170						47,170		*
NORTHLEA PARTNERS LTD	⁽¹⁾		22,760		10,968		11,792						11,792		*
PABLO FALABELLA	⁽⁷⁾		15,000		15,000		-						-		-
PANTHER CONSULTING INC	⁽⁶⁾		217,000		60,000		-						157,000		*
PAUL GLAUBER	⁽¹⁾		21,576		9,784		11,792						11,792		*
PAUL P ALATI	⁽¹⁾		41,508		29,716		11,792						11,792		*
PAULSON INVESTMENT COMPANY LLC	⁽³⁾		309,511		139,432		170,079						170,079		*
PEDRITO FALABELLA	⁽⁶⁾		20,000		20,000		-						-		-
PEDRO FALABELLA	⁽⁶⁾		60,000		60,000		-						-		-
PETER COLETTIS	⁽¹⁾		39,924		18,698		21,226						21,226		*
Peter Fogarty	⁽³⁾		89,859		-		89,859						89,859		*
PINEWOOD TRADING FUND LP	⁽⁷⁾		76,593		60,000		-						16,593		*
PLATINUM POINT CAPITAL LLC	⁽⁴⁾		966,463		341,463		625,000				341,463		625,000		1.25	%
POI LLC	⁽⁷⁾		111,368		60,000		-						51,368		*
PORTER PARTNERS LP	⁽¹⁾		380,374		191,695		188,679						188,679		*
RALPH WHARTON	⁽¹⁾		67,697		32,320		35,377						35,377		*
RANDY RABIN	⁽¹⁾		21,585		9,793		11,792						11,792		*
RANDY SEARS	⁽⁷⁾		14,286		14,286		-						-		-
RIAZUL HUDA	⁽⁷⁾		678,549		60,000		-						618,549		1.25	%
ROBERT A JUVE	⁽¹⁾		136,274		66,463		69,811						69,811		*
ROBERT BECK	⁽¹⁾		83,146		59,561		23,585						23,585		*
ROBERT HOROWITZ	⁽¹⁾		83,647		36,477		47,170						47,170		*
ROBERT HUPFER	⁽¹⁾		41,508		29,716		11,792						11,792		*
ROBERT MONROE	⁽¹⁾		195,622		101,282		94,340						94,340		*
ROBERT SETTEDUCATI	⁽³⁾		83,349		83,349		-						-		-
ROGER WRIGHT	⁽⁷⁾		14,285		14,285		-						-		-
RON HOLMAN	⁽⁷⁾		14,500		14,500		-						-		-
RONALD AHMANN	⁽⁷⁾		14,500		14,500		-						-		-
RONALD WEAVER	⁽¹⁾		24,386		11,650		12,736						12,736		*
RWH PROPERTIES LLC	⁽⁷⁾		22,732		22,732		-						-		-
RZI CONSULTING LLC	⁽⁶⁾		25,000		25,000		-						-		-
SANDRA MARCINKO	⁽⁷⁾		14,286		14,286		-						-		-
SANTIAGO LOZA	⁽⁷⁾		5,000		5,000		-						-		-

Name of Selling Stockholder		Number of Shares Beneficially Owned #		Shares of Common Stock Offered by the Selling Stockholder		Shares Underlying Warrants		Shares Underlying Exchangeable Shares		Unconverted Convertible Notes Outstanding (assuming VWAP of $3)		Unregistered Shares Beneficially Owned After Offering Number		% of Shares Owned After Offering Percent

SEAN MCCANCE	⁽¹⁾		589,566		282,962		306,604						306,604		*
SHANKAR DAS	⁽¹⁾		24,183		12,391		11,792						11,792		*
SOHAIRA SIDDIQUI	⁽⁷⁾		758,845		60,000		-						698,845		1.40	%
STARGAZER ORIGINALS	⁽⁷⁾		14,286		14,286		-						-		-
STARLA GOFF	⁽⁷⁾		1,536		1,536		-						-		-
STEPHEN CONNOR	⁽¹⁾		22,674		10,882		11,792						11,792		*
STEVEN R ROTHSTEIN	⁽¹⁾		27,067		12,916		14,151						14,151		*
SUSAN ROGERS	⁽⁷⁾		21,124		21,124		-						-		-
SYED AHSAN ASLAM	⁽⁷⁾		119,693		60,000		-						59,693		*
SYED MUNIRUDDIN HASAN	⁽⁷⁾		7,357		7,357		-						-		-
SYED SALMAN RAZZAQI	⁽⁷⁾		12,017		12,017		-						-		-
Tarek Fakhuri (1)	⁽⁵⁾		47,877		47,877		-		47,877				-		-
THE CLEMETSON FAMILY TRUST	⁽⁷⁾		3,900		3,900		-						-		-
THE GBS LIVING TRUST	⁽¹⁾		82,873		45,138		37,735						37,735		*
THOMAS ENDRES	⁽³⁾		3,537		3,537		-						-		-
THOMAS GATELY	⁽¹⁾		36,898		18,030		18,868						18,868		*
THOMAS GRUBER	⁽¹⁾		179,735		85,395		94,340						94,340		*
THOMAS H BUTCHER	⁽¹⁾		45,849		45,849		-						-		-
THOMAS MCCHESNEY	⁽¹⁾		12,689		12,689								-		-
THOMAS NOLAN	⁽¹⁾		90,712		43,542		47,170						47,170		*
THOMAS PARIGIAN	⁽³⁾		72,761		72,761		-						-		-
Vaani Sigamany (1)	⁽⁵⁾		23,938		23,938		-		23,938				-		-
VERENA FABIAN	⁽¹⁾		49,996		35,845		14,151						14,151		*
VERONICA MARANO	⁽¹⁾		270,382		128,872		141,510						141,510		*
VIJAY PATEL	⁽¹⁾		64,787		29,410		35,377						35,377		*
WAMOH LLC	⁽¹⁾		66,041		30,664		35,377						35,377		*
WAYNE WESTERMAN	⁽¹⁾		45,276		21,691		23,585						23,585		*
WILD WEST CAPITAL	⁽²⁾		239,334		121,409		117,925						117,925		*
WILLIAM H COSTIGAN	⁽¹⁾		17,371		10,296		7,075						7,075		*
WILLIAM M STOCKER III	⁽¹⁾		135,265		64,510		70,755						70,755		*
ZORAN CHURCHIN	⁽⁶⁾		52,401		52,401		-						-		-
Total			26,684,865		10,947,201		6,299,401		1,442,782		624,009		15,737,664		31.5	%

# Includes shares of Common Stock underlying warrants in certain cases, which shares will not be registered under this registration statement.

* Denotes less than 1%.

(1) Shares underlying first series of Series A Notes issued from June 2020 to February 2021.

(2) Shares underlying second series of Series A Notes issued from December 2020 to February 2021.

(3) Shares underlying Placement Agent compensation costs associated with the issuance Series A Notes; share-based compensation was issued in February 2021.

(4) Shares underlying Series B Notes issued in February 2021.

(5) Shares underlying Exchangeable Shares issued to investors as part of the Company’s reverse take-over of iMedical Innovations Inc. in February 2016.

(6) Shares issued to advisors and consultants pursuant to compensation arrangements with the Company between February 2016 and April 2022.

(7) Shares issued pursuant to private placement arrangements between February 2016 and June 2020.

(8) Shares beneficially owned by Arthur Hiess for the benefit of Judith Kucharsky, Rebecca Kucharsky Hiess, and Jordana Kucharsky Hiess.

(9) Of the 1,146,345 beneficially owned by Mir Amir Ali, 125,000 each owned for the benefit of Aisha Amir Ali and Anisha Ali Malik.

PLAN OF DISTRIBUTION

Our Common Stock is quoted on the Nasdaq Capital Market (the “Trading Market”) under the symbol “BTCY.”

The selling stockholder will act independently of us in making decisions with respect to the timing, manner and size of each and any sale.

The selling stockholder, which, as used herein, includes donees, pledgees, transferees or other successors-in-interest selling shares of Common Stock previously issued or interests in shares of Common Stock received after the date of this prospectus from the Selling Stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell any or all of the securities covered hereby on the Trading Market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. The Common Stock may be sold in one or more transactions at fixed prices, and, if and when our Common Stock is regularly quoted on an over-the-counter market or on a national securities exchange, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. The selling stockholder may use any one or more of the following methods when selling the Common Stock:

●

ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

●

block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;

●

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

●

an exchange distribution in accordance with the rules of the applicable exchange;

●

privately negotiated transactions;

●

settlement of short sales;

●

in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such securities at a stipulated price per security;

●

through the writing or settlement of options or other hedging transaction whether through an options exchange or otherwise;

●

a combination of any such methods of sale; or

●

any other method permitted pursuant to applicable law

The selling stockholder may also sell securities under Rule 144 under the Securities Act of 1933, as amended, referred to as the Securities Act, if available, or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the selling stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction, a markup or markdown in compliance with FINRA IM-2440.

In connection with the sale of the securities or interests therein, the selling stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The selling stockholder may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The selling stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The selling stockholder may pledge or grant a security interest in some or all of the shares of Common Stock it owns and, if it defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the shares of Common Stock from time to time pursuant to this prospectus or any supplement or amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending, if necessary the selling stockholder list to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholder also may transfer and donate the shares of Common Stock in other circumstances in which case the transferees, donees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

The selling stockholder and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The selling stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.

Once sold under the registration statement of which this prospectus forms a part, the shares of Common Stock will be freely tradable in the hands of persons other than our affiliates. We have agreed to pay certain fees and expenses incurred by the Company incident to the registration of the securities. We have agreed to indemnify the selling stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. The selling stockholder may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.

The securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. To the extent required, the shares of our Common Stock to be sold, the name of the selling stockholder, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.

Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the securities may not simultaneously engage in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholder will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the selling stockholder or any other person. We will make copies of this prospectus available to the selling stockholder and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

DESCRIPTION OF CAPITAL STOCK

Our authorized capital stock consists of 125,000,000 shares of common stock, with a par value of $0.001 per share, and 10,000,000 shares of preferred stock, with a par value of $0.001 per share. As of April 7, 2022, there were 49,927,049 shares of Common Stock issued and outstanding, and 1,466,718 Exchangeable Shares issued and outstanding that convert directly into common shares, which when combined with Common Stock produce an amount equivalent to 51,393,767 outstanding shares upon the exchange of Exchangeable Shares.

Common Stock

Pursuant to Article II of the Amended and Restated By-laws of the Company, each holder of Common Stock and securities exchangeable into Common Stock that vote with the Common Stock are entitled to one vote for each share of Common Stock held of record by such holder with respect to all matters to be voted on or consented to by our stockholders, except as may otherwise be required by applicable Nevada law. Unless the vote of a greater number or voting by classes is required by Nevada statute, the Company’s Articles of Incorporation or its bylaws, in all matters other than the election of directors, the affirmative vote of a majority of the voting power of the capital stock (or securities exchangeable in accordance with their terms into capital stock of the Company) present in person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the shareholders. Furthermore, except as otherwise required by law, the Company’s Articles of Incorporation or its bylaws, directors shall be elected by a plurality of the voting power of the capital stock (or securities exchangeable in accordance with their terms into capital stock of the Company) present in person or represented by proxy at the meeting and entitled to vote on the election of directors.

The stockholders do not have pre-emptive rights under our Certificate of Incorporation to acquire additional shares of Common Stock or other securities. The Common Stock is not being subject to redemption rights and carries no subscription or conversion rights. In the event of liquidation of the Company, the stockholders will be entitled to share in corporate assets on a pro rata basis after the Company satisfies all liabilities and after provision is made for each class of capital stock having preference over the Common Stock (if any). Subject to the laws of the State of Nevada, if any, of the holders of any outstanding series of preferred stock, the Board of Directors will determine, in their discretion, to declare dividends advisable and payable to the holders of outstanding shares of Common Stock. Shares of our Common Stock are subject to transfer restrictions.

Blank-Check Preferred Stock

We are currently authorized to issue up to 10,000,000 shares of blank check preferred stock, $0.001 par value per share, of which one share has currently been designated as the Special Voting Preferred Stock (as described below). The Board of Directors has the discretion to issue shares of preferred stock in series and, by filing a Preferred Stock Designation or similar instrument with the Nevada Secretary of State, to establish from time to time the number of shares to be included in each such series, and to fix the designation, power, preferences and rights of the shares of each such Series and the qualifications, limitations and restrictions thereof.

Preferred stock is available for possible future financings or acquisitions and for general corporate purposes without further authorization of stockholders unless such authorization is required by applicable law, the rules of the securities exchange or market on which our stock is then listed or admitted to trading.

Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes could, under some circumstances, have the effect of delaying, deferring or preventing a change in control of the Company.

A prospectus supplement relating to any series of preferred stock being offered will include specific terms relating to the offering. Such prospectus supplement will include:

	●	the title and stated or par value of the preferred stock;

	●	the number of shares of the preferred stock offered, the liquidation preference per share and the offering price of the preferred stock;

	●	the dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation thereof applicable to the preferred stock;

	●	whether dividends shall be cumulative or non-cumulative and, if cumulative, the date from which dividends on the preferred stock shall accumulate;

	●	the provisions for a sinking fund, if any, for the preferred stock;

	●	any voting rights of the preferred stock;

	●	the provisions for redemption, if applicable, of the preferred stock;

	●	any listing of the preferred stock on any securities exchange;

	●	the terms and conditions, if applicable, upon which the preferred stock will be convertible into our common stock, including the conversion price or the manner of calculating the conversion price and conversion period;

	●	if appropriate, a discussion of Federal income tax consequences applicable to the preferred stock; and

	●	any other specific terms, preferences, rights, limitations or restrictions of the preferred stock.

The terms, if any, on which the preferred stock may be convertible into or exchangeable for our common stock will also be stated in the preferred stock prospectus supplement. The terms will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option, and may include provisions pursuant to which the number of shares of our common stock to be received by the holders of preferred stock would be subject to adjustment.

Special Voting Preferred Stock

The Board authorized the designation of a class of the Special Voting Preferred Stock, with the rights and preferences specified below. For purposes of deferring Canadian tax liabilities that would be incurred by certain of our shareholders, iMedical and its shareholders have entered into a transaction pursuant to which the eligible holders, who would have otherwise received shares of common stock of the Company pursuant to the Acquisition Transaction, received Exchangeable Shares. The right to vote the Common Stock equivalent of such Exchangeable Shares shall be conducted by the vote of the Special Voting Preferred Stock issued to the Trustee.

In that regard, we have designated one share of preferred stock as the Special Voting Preferred Stock with a par value of $0.001 per share. The rights and preferences of the Special Voting Preferred Stock entitle the holder (the Trustee and, indirectly, the holders of the Exchangeable Shares) to the following:

● the right to vote in all circumstances in which holders of our common stock have the right to vote, with the common stock as one class;

● an aggregate number of votes equal to the number of shares of our common stock that are issuable to the holders of the outstanding Exchangeable Shares;

● the same rights as the holders of our common stock as to notices, reports, financial statements and attendance at all stockholder meetings;

● no entitlement to dividends; and

● a total sum of $1.00 upon windup, dissolution or liquidation of the Company.

The Company may cancel the Special Voting Preferred Stock when there are no Exchangeable Shares outstanding and no option or other commitment of iMedical of its affiliates, which could require iMedical or its affiliates to issue more Exchangeable Shares.

As set forth above, the holders of the Exchangeable Shares, through the Special Voting Preferred Stock, have voting rights and other attributes corresponding to the Common Stock. The Exchangeable Shares provide an opportunity for Eligible Holders to obtain a full deferral of taxable capital gains for Canadian federal income tax purposes in specified circumstances.

Series A Preferred Stock

On December 19, 2019, the Company entered into a Securities Purchase Agreement with one accredited investor. Pursuant to the SPA, the company sold 6,000 Shares of its Series A convertible Preferred Stock at a per share price of $1,000 per preferred share and received gross proceeds of $6,000,000.

On May 22, 2020, another 215 Series A preferred shares were issued as a result of a combined transaction that included the conversion of $100,000 in promissory notes and $15,000 in accrued interest for 115 preferred shares, as well as a purchase of 100 preferred shares for cash proceeds of $100,000.

The Company filed the Certificate of Designations with the Secretary of State of Nevada a Certificate of Designation of Rights, Powers, Preferences, Privileges and Restrictions of Series A Convertible Preferred Stock (the “Certificate of Designations) with the Sectary of State of the State of Nevada.

Pursuant to the Certificate of Designations the Company designated 20,000 shares of preferred stock as Series A Convertible Preferred Stock (the “Series A Preferred”). The Series A Preferred will not be entitled to any voting rights except as may be required by applicable law.

Commencing 24 months after the issuance date of the Series A Preferred subject to the beneficial ownership limitations in the Certificate of Designations and the Company’s right of redemption, and the holder of Series A Preferred may convert the Series A Preferred into shares of the Company’s common stock on a monthly basis up to 5% of the aggregate amount of the e aggregate amount of the purchase price of the Series A Convertible Preferred purchased by such Holder as adjusted (reduced) to reflect any Series A Convertible Preferred that the Holder has previously converted or no longer owns at a conversion price equal to the greater of $.001 or a 15% discount to the VWAP (as defined in the Certificate of Designations) for the (Company’s Common Stock) five Trading Days immediately prior to the conversion date (the “Conversion Rate”). Additionally, the Company and the Holder may agree to exchange such Holder’s outstanding Preferred Shares for shares of common stock in any common stock financing being conducted by the Company at a 15% discount to the pricing of that financing. Except as required by law the Preferred Shares shall not have any liquidation rights.

From and after the first date of issuance of any Preferred Shares (the “Initial Issuance Date”), dividends shall be paid at the rate of 12% per annum of the amount of the Holder’s (each a “Holder” and collectively the “Holders”) purchase price for the Preferred Shares pursuant to the Securities Purchase Agreement (or similar agreement) between the Company and the Purchaser as adjusted (reduced) to reflect any Series Convertible Preferred That the Holder has previously converted or no longer owns and such dividend shall be paid quarterly provided that the Holder and the Company may mutually agree to accrue and defer any such dividend

The Company may redeem all or part of the outstanding Preferred Shares (i) pursuant to Section 4(c) of the Certificate of Designations and/or (ii) after one year from the date of issuance of such Preferred Shares, by paying an amount equal to the aggregate purchase price paid by the Holder for the Preferred Shares as adjusted (reduced) to reflect any Preferred Shares that the Holder no longer owns multiplied by 110% plus accrued dividends. The Company may exercise its right to redemption by giving notice to the Holders whose Preferred Shares it is seeking to redeem along with the terms and the amounts of such redemption and at such time as the Holder receives a notice of such redemption then the Holder may no longer convert such Preferred Shares and such Preferred Shares shall be deemed to no longer be outstanding.

The Series A Convertible Preferred were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act since, among other things, the transactions did not involve a public offering.

Under the Certificate of Designations no time may all or a portion of the Series A Convertible Preferred Stock be converted if the number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common Stock owned by the Holder at such time, the number of shares of Common Stock that would result in the Holder beneficially owning (as determined in accordance with Section 13(d) of the 1934 Act and the rules thereunder) more than 4.99% of all of the Common Stock outstanding at such time (the “4.99% Beneficial Ownership Limitation”); provided, however, that, upon the Holder providing the Company with sixty-one (61) days’ advance notice (the “4.99% Waiver Notice”) that the Holder would like to waive this Section 4(e) with regard to any or all shares of Common Stock issuable upon conversion of the Preferred Shares, this Section 4(e) will be of no force or effect with regard to all or a portion of the Series A Convertible Preferred Stock referenced in the 4.99% Waiver Notice but shall in no event waive the 9.99% Beneficial Ownership Limitation.

Warrants and Options

As of April 7, 2022, the Company had outstanding warrants and options, to purchase 10,583,644 shares of common stock and 5,302,660 shares of common stock, respectively, with various exercise prices and expiration dates.

Transfer Agent and Registrar

Action Stock Transfer Corporation is the transfer agent for our shares of common stock. Its address is 2469 E. Fort Union Blvd., Suite 214, Salt Lake City, UT 84121; Telephone: (801) 274-1088.

Listing

Our Common Stock is traded on the Nasdaq Capital Market under the symbol “BTCY”.

LEGAL MATTERS

The validity of the issuance of the securities offered by this prospectus will be passed upon for us by Sichenzia Ross Ference LLP, New York, New York.

EXPERTS

The consolidated financial statements of Biotricity Inc. as of and for the years ended March 31, 2021 and 2020 appearing in Biotricty Inc. Annual Report on Form 10-K for the year ended March 31, 2021 have been audited by SRCO Professional Corporation, Chartered Professional Accountants as set forth in its report thereon, included therein, and incorporated by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION

We file annual, quarterly and special reports, along with other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s website at http://www.sec.gov. You may also read and copy any document we file at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room.

This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities offered hereby under the Securities Act of 1933, as amended. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s internet site.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

This prospectus is part of a registration statement filed with the SEC. The SEC allows us to “incorporate by reference” into this prospectus the information that we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. The following documents are incorporated by reference and made a part of this prospectus:

	●	our Annual Report on Form 10-K for the year ended March 31, 2021 filed with the SEC on June 22, 2021

	●	our Quarterly Report on Form 10-Q/A for the period ended June 30, 2021 filed with the SEC on August 17, 2021, the Quarterly Report on Form 10-Q for the period ended September 30, 2021 filed with the SEC on November 5, 2021, and the Quarterly Report on Form 10-Q for the period ended December 31, 2021 filed with the SEC on February 14, 2022;

	●	our Current Reports on Form 8-K filed with the SEC on April 15, 2021; June 17, 2021, August 31, 2021, September 10, 2021, September 13, 2021, November 5, 2021, December 7, 2021, December 8, 2021, and December 28, 2021;

	●	our Current Report on From 8-K/A filed with the SEC on April 27, 2021;

	●	the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on August 25, 2021 (File No. 000-56074), including any amendment or report filed for the purpose of updating such description and

	●	all reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus and prior to the termination of this offering.

Notwithstanding the foregoing, information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this prospectus.

The information about us contained in this prospectus should be read together with the information in the documents incorporated by reference. You may request a copy of any or all of these filings, at no cost, by writing or telephoning us at: Waqaas Al-Siddiq, Biotricity Inc., 203 Redwood Shores Parkway, Suite 600, Redwood City, CA 94065, telephone number (650) 832-1626.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 14. Other Expenses of Issuance and Distribution.

The Company is paying all expenses of the offering. The following table sets forth all expenses to be paid by the registrant. All amounts shown are estimates except for the registration fee.

Item	Amount
SEC registration fee	$	2,212.28
Legal fees and expenses		*
Accounting fees and expenses		*
Miscellaneous expenses		*

Total	$	*

*	These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time. The applicable prospectus supplement will set forth the estimated amount of expenses of any offering of securities.

Item 15. Indemnification of Directors and Officers.

Nevada Revised Statute (“NRS”) Section 78.7502 provides that a corporation shall indemnify any director, officer, employee or agent of a corporation against expenses, including attorneys’ fees, actually and reasonably incurred by him in connection with any the defense to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue or matter therein.

NRS 78.7502(1) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

NRS Section 78.7502(2) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys’ fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

II-1

NRS Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.

The Registrant’s Articles of Incorporation and Bylaws provide that it shall indemnify its directors, officers, employees and agents to the full extent permitted by NRS, including in circumstances in which indemnification is otherwise discretionary under such law.

These indemnification provisions may be sufficiently broad to permit indemnification of the Registrant’s officers, directors and other corporate agents for liabilities (including reimbursement of expenses incurred) arising under the Securities Act of 1933.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the company pursuant to the foregoing provisions, or otherwise, the Registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.

The Registrant has the power to purchase and maintain insurance on behalf of any person who is or was one of the Registrant’s directors or officers, or is or was serving at the Registrant’s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other business against any liability asserted against the person or incurred by the person in any of these capacities, or arising out of the person’s fulfilling one of these capacities, and related expenses, whether or not the Registrant would have the power to indemnify the person against the claim under the provisions of the NRS. The Registrant does not currently maintain director and officer liability insurance on behalf of its director and officers; however, it intends to so purchase and maintain such insurance when economically feasible.

Item 16. Exhibits.

Exhibit
Number		Description of Document

4.1		Amended and Restated Articles of Incorporation (filed as Exhibit 3(i) to the Registrant’s Current Report on Form 8-K filed with the SEC on February 3, 2016 and incorporated herein by reference).*
4.2		Amended and Restated By-Laws (filed as Exhibit 3(ii) to the Registrant’s Current Report on Form 8-K filed with the SEC on February 3, 2016 and incorporated herein by reference).*
4.3		Certificate of Designation of Preferences, Rights and Limitations of Special Voting Preferred Stock of Biotricity Inc. (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 3, 2016 and incorporated herein by reference).*
4.4		Certificate of Designation of Rights, Powers, Preferences, Privileges and Restrictions of Series A Convertible Preferred Stock (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on December 23, 2019 incorporated herein by reference).*
4.5		Form of Subscription Agreement (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 6, 2020).*
4.6		Form of Convertible Promissory Note (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 6, 2020).*
4.7		Form of Warrant (filed as Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 6, 2020).*
4.8		Form of Registration Rights Agreement (filed as Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 6, 2020).*
4.9		Form of Subscription Agreement (filed as Exhibit 10.1 to the Registrant’s Current on Form 8-K filed with the SEC on January 22, 2021).*
		Form of Convertible Promissory Note (filed as Exhibit 10.2 to the Registrant’s Current on Form 8-K filed with the SEC on January 22, 2021).*
4.10		Form of Registration Rights Agreement (filed as Exhibit 10.4 to the Registrant’s Current on Form 8-K filed with the SEC on January 22, 2021).*
5.1		Opinion of Sichenzia Ross Ference LLP**
23.1		Consent of SRCO Professional Corporation
23.2		Consent of Sichenzia Ross Ference LLP (contained in Exhibit 5.1).
107		Filing Fees Exhibit

* Previously Filed

** To be filed by amendment.

II-2

Item 17. Undertakings

(a) The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

provided, however, Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the registration statement is on Form S-3 or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3)shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

II-3

(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or (5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b) The registrant hereby undertakes that for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

(d) The registrant hereby undertakes that:

(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II-4

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on April 8, 2022.

	BIOTRICITY INC.

	By:	/s/ Waqaas Al-Siddiq
		Waqaas Al-Siddiq
	Its:	Chairman, President and Chief Executive Officer (principal executive officer)

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities indicated on April 8, 2022.

Signature	Title	Date

/s/ Waqaas Al Siddiq	Chairman of the board, President and Chief Executive	APRIL 8, 2022
Waqaas Al Siddiq	Officer (principal executive officer)

/s/ John Ayanoglou	Chief Financial Officer
John Ayanoglou	(principal financial and accounting officer)	APRIL 8, 2022

*
Norman M. Betts	Director
		APRIL 8, 2022
*
David A. Rosa	Director

*	Director	APRIL 8, 2022
Patricia Kennedy

*	Director	APRIL 8, 2022
Steve Salmon

* The undersigned by signing his name hereto signs and executes this Amendment No. 1 to Registration Statement on Form S-3 pursuant to the Powers of Attorney executed by the above named signatories and previously filed with the Commission on January 21, 2022.

	By:	/s/ Waqaas Al-Siddiq
	Name:	Waqaas Al-Siddiq, Attorney-in-Fact

II-5

Biotricity (QB) (USOTC:BTCY)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Click aqui para mais gráficos Biotricity (QB).

Biotricity (QB) (USOTC:BTCY)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024

Dados

Notícias

Ferramentas

Mercados

Comunidade

Recursos principais

Follow Feed

Fluxo de Opções

Monitor

BTCY Biotricity Inc (QB)

Notícias Biotricity Inc.

Seu Histórico Recente

Empresa

Negócios

Popular

Obter o aplicativo

Tendências Agora

Rankings